Boston Scientific Corporation (NYSE: BSX) Investor Alert: Deadline in Lawsuit on May 4, 2026

A deadline is coming up on May 4, 2026 in the lawsuit filed for certain investors of Boston Scientific Corporation (NYSE: BSX) over alleged securities laws violations by Boston Scientific Corporation.

Investors who purchased shares of Boston Scientific Corporation (NYSE: BSX) have certain options and there are strict and short deadlines running. Deadline: May 4, 2026. Boston Scientific Corporation (NYSE: BSX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Marlborough, MA based Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. Boston Scientific Corporation (NYSE: BSX) reported that its annual Total Revenue rose from over $16.74 billion in 2024 to over $20.07 billion in 2025, and that its Net Income increased from over $1.85 billion in 2024 to over $2.89 billion in 2025.

On February 4, 2026, Boston Scientific Corporation published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and assertions they "have a very good understanding of what competition we will face and in what time frame."

Shares of Boston Scientific Corporation (NYSE: BSX) declined from $109.50 per share on September 09, 2025, to as low as $67.56 per share on March 12, 2026.

According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Boston Scientific Corporation (NYSE: BSX) common shares between July 23, 2025 and February 3, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 23, 2025 and February 3, 2026, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to Boston Scientific's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations, and that Boston Scientific's ambition of continuing "to grow our share in the overall EP market" to maintain a growth trajectory at "2x the market" had fallen short of reality because Boston Scientific had begun to experience new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting its growth potential.

Those who purchased shares of Boston Scientific Corporation (NYSE: BSX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.